Huichuang Medical Snares ￥10M in Series A Funding Round

According to VCBeat, Recently, Danyang Huichuang Medical Device Co., Ltd. ("Huichuang Medical") has closed a Series A funding round of tens of millions, led by the existing investor Qingyuan Investment, which participated in the Pre-A round of Huichuang Medical at the end of 2018. This round of financing will be mainly used for R&D, market development and operation.

Huichuang Medical focuses on the R&D of near-infrared (NIR) imaging and evaluation. The company has a top scientific research team and become a leader in the field of NIR. It takes on a number of national projects including the national key research and development plan. The products of Huichuang Medical have been used in more than 60 grade A hospitals and scientific research units.

As a new generation of noninvasive quantitative imaging techniques of brain function, NIR has the advantage of more flexible applications in various scenarios compared with functional MRI and other techniques. It can make the quantitative examination and evaluation of brain function with a high resolution during the movement and treatment of patients, providing an unprecedented way for the diagnosis and treatment of brain diseases.

Wang Daifa, the chief scientist, founder and chairman of Huichuang Medical has rich experience in NIR of more than 10 years. The R&D of the high-performance product led by him has great indicators compared with other counterparts, which is the world's first device (NirScan) with over 100 channels approved by NMPA, making it possible for whole-brain imaging.

Pan Haifeng, the general manager and partner of Qingyuan Investment, said, "The R&D in brain science and the diagnosis and treatment of brain diseases caused by brain dysfunction is the world's hotspot in the next decade, which is expected to be a trillion-dollar market. NIR effectively realize the direct observation of brain function during the diagnosis and treatment."

Founded in 1999, Qingyuan Investment focuses on the investment of science and technology in the middle and early stage, with AUM over 7 billion yuan. The company has invested in more than 200 companies in the fields of IT, healthcare, advanced manufacturing, clean technology, and others.